Financials in USD. Standardized financial statements.
A compact view of how Aligos Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.19M | $3.94M | $15.53M | $13.91M | $4.36M | $0 | $0 | $0 |
| Revenue Growth? | -44.6% | -74.6% | +11.7% | +219.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $930,000 | $0 | $0 | $0 | $0 | $3.33M | $2.30M | $1.29M |
| Gross Profit? | $1.26M | $3.94M | $15.53M | $13.91M | $4.36M | -$3.33M | -$2.30M | -$1.29M |
| Gross Margin? | +57.5% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $89.24M | $93.10M | $103.66M | $111.49M | $132.68M | $94.51M | $54.04M | $13.66M |
| Operating Income? | -$87.98M | -$89.15M | -$88.13M | -$97.58M | -$128.32M | -$97.83M | -$54.04M | -$13.66M |
| EBITDA? | -$87.06M | -$86.53M | -$85.06M | -$93.91M | -$124.54M | -$105.06M | -$49.88M | -$12.37M |
| Income Before Tax | -$23.88M | -$130.88M | -$86.88M | -$95.94M | -$128.19M | -$108.38M | -$52.18M | -$13.93M |
| Income Tax Expense | $314,000 | $331,000 | $795,000 | $106,000 | $143,000 | $161,000 | $85,000 | $0 |
| Net Income? | -$24.19M | -$131.21M | -$87.68M | -$96.05M | -$128.33M | -$108.54M | -$52.26M | -$13.93M |
| EPS? | $-2.45 | $-20.94 | $-3.52 | $-2.25 | $-3.22 | $-3.18 | $-2.38 | $-0.66 |
| Diluted EPS? | $-2.45 | $-20.94 | $-3.52 | $-2.25 | $-3.22 | $-3.18 | $-2.38 | $-0.66 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality